Item 7.01. Regulation FD Disclosure.

On December 21, 2021, PhaseBio Pharmaceuticals, Inc. (the "Company") issued a press release entitled "PhaseBio Provides Pemziviptadil (PB1046) Program Update." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

Item 8.01. Other Events.

On December 21, 2021, the Company announced that it is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension due to COVID-19 impacts on manufacturing, associated drug supply and the rate of enrollment in the study. The Company will analyze the trial data to determine an appropriate path forward for the program. With the suspension of the Phase 2b trial, the Company will reprioritize resources and capital towards pre-commercialization activities of bentracimab and the advancement of other pipeline programs, including PB6440 for resistant hypertension.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits
    Exhibit No.                                           Description

99.1                         Press Release, dated December 21, 2021, entitled "PhaseBio Provides
                           Pemziviptadil (PB1046) Program Update".

104                        Cover page interactive data file (formatted as Inline XBRL).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses